Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib + Durvalumab in ALK+ NSCLC
NCT02898116Phase 2Completed
- Sponsor
- Ludwig Cancer Research
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Ludwig Cancer Research. Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events up to 3 months. Started May 2017; status: completed.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02898116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02898116.